Overseas revenue plummets, dragging down performance; the fundraising projects of Ota Biotechnology are delayed.

① Due to the impact of international situations, economic policies, and fluctuations in the overall market, the fundraising projects of Aotai Biological aimed at expanding overseas markets will be delayed. ② Overseas revenue has always been the most core source of income for Aotai Biological, with the overall income proportion once reaching 99.83%, and the sharp decline in overseas revenue has also led to a significant drop in Aotai Biological's overall income.

cls.cnDec 26 03:37 ET

After investing 1.5 billion over three years to build a Global research and development headquarters, can Zhejiang Orient Gene Biotech win this "turnaround battle"?

① Zhejiang Orient Gene Biotech spent 0.29 billion yuan to acquire land in Zhangjiang, planning to build a global digital research and development innovation headquarters project with a total investment of 1.5 billion yuan, expected to achieve annual sales revenue of 1.5 billion yuan upon reaching production capacity. ② After the demand for nucleic acid testing declined, Zhejiang Orient Gene Biotech encountered a performance "slump", remaining in a net loss of over 260 million yuan until the first three quarters of 2024.

cls.cnDec 13 03:28 ET

Jiangsu Skyray Instrument has been designated as a special treat and fined 3 million yuan. In recent years, there have been 10 other instances of illegal operation in production and management. | Quick read of the announcement.

① Jiangsu Skyray Instrument was fined 3 million yuan by the Securities Regulatory Commission, and several executives including chairman Liu Zhaogui were also penalized; ② The company's stocks will be subject to other risk warnings by the Shenzhen Stock Exchange, changed to "ST Jiangsu Skyray"; ③ In recent years, the company has faced up to 10 cases of violations related to environmental protection, safety regulations, and other operational misconduct.

cls.cnDec 8 07:46 ET

Former Alibaba CEO Wei Zhe joins sansure biotech inc. Latest response: will not involve business related to mergers and acquisitions by Sanshong.

①Wei Zhe expressed that the reason for joining sansure biotech inc. was to deeply empower the medical industry and gain in-depth understanding of the medical industry; ②He recently posted on his Moments saying that his ideas are highly consistent with sansure biotech inc. and the company's director and general manager, and he will deeply cultivate the sinking medical system and layout the blueprint for going global; ③At the end of last year, Wei Zhe and his founded Jia Yu Capital began to get involved in the medical health field, and announced the establishment of Jia Yu-Ziniu Medical Fund with Ziniu Fund.

cls.cnDec 1 22:01 ET

Autobio Diagnostics: Molecular sector is growing rapidly, subsidiary disputes may be resolved soon | Earnings Conference

① The secretary of the board of directors of autobio diagnostics stated at the earnings conference that the significant increase in R&D expenses led to a decline in Q3 net income attributable to the parent company; ② The chairman of autobio diagnostics, Miao Yongjun, informed investors that the molecular sector is expected to maintain high-speed growth, while the microbiology sector will achieve steady growth of 15%-20% each year.

cls.cnNov 25 06:44 ET

Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.

cls.cnNov 13 08:52 ET